266 related articles for article (PubMed ID: 28639119)
1. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
[TBL] [Abstract][Full Text] [Related]
2. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects.
Kaufmann P; Niglis S; Bruderer S; Segrestaa J; Äänismaa P; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2015 Oct; 80(4):670-7. PubMed ID: 25851691
[TBL] [Abstract][Full Text] [Related]
3. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects.
Bruderer S; Petersen-Sylla M; Boehler M; Remeňová T; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2017 Dec; 83(12):2778-2788. PubMed ID: 28715853
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
5. Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist Selexipag.
Boehler M; Bruderer S; Ulč I; Dingemanse J
Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):115-120. PubMed ID: 28639216
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects.
Bruderer S; Hurst N; Kaufmann P; Dingemanse J
Pharmacology; 2014; 94(3-4):148-56. PubMed ID: 25277144
[TBL] [Abstract][Full Text] [Related]
7. Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist.
Kaufmann P; Hurst N; Astruc B; Dingemanse J
Eur J Clin Pharmacol; 2017 Feb; 73(2):151-156. PubMed ID: 27885399
[TBL] [Abstract][Full Text] [Related]
8. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study.
Baldoni D; Bruderer S; Muhsen N; Dingemanse J
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):788-98. PubMed ID: 26152132
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Kaufmann P; Cruz HG; Krause A; Ulč I; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2016 Aug; 82(2):369-79. PubMed ID: 27062188
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag.
Kaufmann P; Okubo K; Bruderer S; Mant T; Yamada T; Dingemanse J; Mukai H
Am J Cardiovasc Drugs; 2015 Jun; 15(3):195-203. PubMed ID: 25850750
[TBL] [Abstract][Full Text] [Related]
13. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
15. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
16. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.
Zdravkovic M; Olsen AK; Christiansen T; Schulz R; Taub ME; Thomsen MS; Rasmussen MH; Ilondo MM
Eur J Clin Pharmacol; 2003 Feb; 58(10):683-8. PubMed ID: 12610745
[TBL] [Abstract][Full Text] [Related]
17. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
18. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
19. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
20. Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects.
Bruderer S; Okubo K; Mukai H; Mant T; Dingemanse J
Clin Ther; 2016 May; 38(5):1228-1236.e1. PubMed ID: 27063071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
